medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2018, Number 2

<< Back Next >>

Ann Hepatol 2018; 17 (2)

Results of Liver Transplantation for Hepatocellular Carcinoma in a Multicenter Latin American Cohort Study

Piñero F, Costa P, Boteon YL, Hoyos DS, Marciano S, Anders M, Varón A, Zerega A, Poniachik J, Soza A, Padilla MM, Menéndez J, Zapata R, Vilatoba M, Muñoz L, Maraschio M, Fauda M, McCormack L, Gadano A, Boin ISF, Parente GJH, Silva M

Language: English
References: 33
Page: 256-267
PDF size: 275.03 Kb.


ABSTRACT

Background and aims. Heterogeneous data has been reported regarding liver transplantation (LT) for hepatocellular carcinoma (HCC) in Latin America. We aimed to describe treatment during waiting list, survival and recurrence of HCC after LT in a multicenter study from Latin America. Material and methods. Patients with HCC diagnosed prior to transplant (cHCC) and incidentally found in the explanted liver (iHCC) were included. Imaging-explanted features were compared in cHCC (non-discordant if pre and post-LT were within Milan, discordant if pre-LT was within and post-LT exceeding Milan). Results. Overall, 435 patients with cHCC and 92 with iHCC were included. At listing, 81% and 91% of cHCC patients were within Milan and San Francisco criteria (UCSF), respectively. Five-year survival and recurrence rates for cHCC within Milan, exceeding Milan/within UCSF and beyond UCSF were 71% and 16%; 66% and 26%; 46% and 55%, respectively. Locoregional treatment prior to LT was performed in 39% of cHCC within Milan, in 53% beyond Milan/within UCSF and in 83% exceeding UCSF (p ‹ 0.0001). This treatment difference was not observed according to AFP values (≤100, 44%; 101-1,000, 39%, and › 1,000 ng/mL 64%; p = 0.12). Discordant imaging-explanted data was observed in 29% of cHCC, showing lower survival HR 2.02 (CI 1.29; 3.15) and higher recurrence rates HR 2.34 when compared to AFP ‹100 ng/mL. Serum AFP › 1,000 ng/mL at listing was independently associated with a higher 5-year recurrence rate and a HR of 3.24 when compared to AFP ‹100 ng/mL. Conclusion. Although overall results are comparable to other regions worldwide, pre- LT treatment not only considering imaging data but also AFP values should be contemplated during the next years.


REFERENCES

  1. Adam R, Karam V, Delvart V, O'Grady J, Mirza D, Klempnauer J, Castaing D, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol 2012; 57: 675- 88.

  2. Thuluvath PJ, Guidinger MK, Fung JJ, Johnson LB, Rayhill SC, Pelletier SJ. Liver Transplantation in the United States, 1999-2008. Am J Transplant 2010; 10: 1003-19.

  3. Mazzaferro VV, Regalia EE, Doci RR, Andreola SS, Pulvirenti AA, Bozzetti FF, Montalto MM, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.

  4. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394-403.

  5. Duvoux C, Thoraval FR, Decaens T, Pessione F, Badran H, Piardi T, Francoz C, et al. Liver Transplantation for Hepatocellular Carcinoma: A Model Including α-Fetoprotein Improves the Performance of Milan Criteria. Gastroenterology 2012; 143: 986-94.

  6. Toso C, Asthana S, Bigam DL, Shapiro AMJ, Kneteman NM. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the scientific registry of transplant recipients database. Hepatology 2008; 49: 832-8.

  7. Salvalaggio PR, Caicedo JC, de Albuquerque LC, Contreras A, Garcia VD, Felga GE, Maurette R, et al. Liver Transplantation in Latin America. Transplantation 2014; 98: 241-6.

  8. Piñero F, Marciano S, Anders M, Orozco Ganem F, Zerega A, Cagliani J, Andriani O, et al. Identifying patients at higher risk of hepatocellular carcinoma recurrence after liver transplantation in a multicenter cohort study from Argentina. Eur J Gastroenterol Hepatol 2016; 28: 421-7.

  9. Piñero F, Marciano S, Anders M, Orozco F, Zerega A, Cabrera CR, Tisi Baña M, et al. Screening for liver cancer during transplant waiting list. Eur J Gastroenterol Hepatol 2015; 27: 355-60.

  10. Piñero F, Mendizabal M, Casciato P, Galdame O, Quiros R, Bandi J, Mullen E, et al. Is recurrence rate of incidental hepatocellular carcinoma after liver transplantation similar to previously known HCC? Towards a predictive recurrence score. Ann Hepatol 2014; 13: 211-8.

  11. Gabrielli M, Vivanco M, Hepp J, Martínez J, Pérez R, Guerra J, Arrese M, et al. Liver Transplantation Results for Hepatocellular Carcinoma in Chile. TPS 2015; 42: 299-301.

  12. Hoyos S, Escobar J, Cardona D, Guzmán C, Mena Á, Osorio G, Pérez C, et al. Factors associated with recurrence and survival in liver transplant patients with HCC--a single center retrospective study. Ann Hepatol 2015; 14: 58-63.

  13. Costa PEG, Vasconcelos JBM, Coelho GR, Barros MAP, Neto BAF, Pinto DSR, Júnior JTV, et al. Ten-Year Experience With Liver Transplantation for Hepatocellular Carcinoma in a Federal University Hospital in the Northeast of Brazil. TPS 2014; 46: 1794-8.

  14. de Ataide EC, Garcia M, Mattosinho TJAP, Almeida JRS, Escanhoela CAF, Boin IFSF. Predicting Survival After Liver Transplantation Using Up-to-Seven Criteria in Patients With Hepatocellular Carcinoma. TPS 2012; 44: 2438-40.

  15. Teixeira AC, Mente D, Castro-e-Silva O, Sankarankutty AK, Cantão CA, Souza FF, Abud D, et al. Treatment of Hepatocellular Carcinoma With Liver Transplantation: A Single-Center Experience From Brazil. TPS 2010; 42: 502-4.

  16. Piñero F, Campaña AG, Mendizabal M, Fauda M, Rowe C, Raffa P, Barreiro M, et al. Domino liver graft with hepatocellular carcinoma used as bridge therapy for a patient with acute liver failure: A case report. Liver Transpl 2014; 20(3): 387-7.

  17. Piñero F, Tisi Baña M, de Ataide EC, Hoyos Duque S, Marciano S, Varón A, Anders M, et al. Liver Transplantation for Hepatocellular carcinoma: Evaluation of the AFP model in a multicenter cohort from Latin America. Liver Int 2016; 36: 1657-67.

  18. Liver EAFTSOT, Cancer EOFRATO. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43.

  19. Yao FY, Breitenstein S, Broelsch CE, Dufour J-F, Sherman M. Does a patient qualify for liver transplantation after the down-staging of hepatocellular carcinoma? Liver Transpl 2011; 17: S109-S116.

  20. Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D, Alsinet C, Cornella H, et al. Combining Clinical, Pathology, and Gene Expression Data to Predict Recurrence of Hepatocellular Carcinoma. Gastroenterology 2011; 140: 1501-12.

  21. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncology 2009; 10: 35-43.

  22. Kneteman N, Livraghi T, Madoff D, de Santibañez E, Kew M. Tools for monitoring patients with hepatocellular carcinoma on the waiting list and after liver transplantation. Liver Transpl 2011; 17: S117-S127.

  23. Elm von E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370: 1453-7.

  24. Salvalaggio PR, Felga G, Axelrod DA, Guardia Della B, Almeida MD, Rezende MB. List and Liver Transplant Survival According to Waiting Time in Patients With Hepatocellular Carcinoma. Am J Transplant 2015; 15: 668-77.

  25. Gruz F, Cleres M, Raffa S and Yantorno S. Hepatocarcinoma dentro y fuera de los criterios de Milán: Resultados de un centro de trasplante hepático en la Argentina. Acta Gastroenterológica Latinoamericana 2013; 43: 106-12.

  26. Decaens T, Roudot-Thoraval F, Badran H, Wolf P, Durand F, Adam R, Boillot O, et al. Impact of tumour differentiation to select patients before liver transplantation for hepatocellular carcinoma. Liv Internat 2011; 31: 792-801.

  27. Sapisochin G, Goldaracena N, Laurence JM, Dib M, Barbas A, Ghanekar A, Clearly SP, et al. The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study. Hepatology 2016; Epub ahead of print.

  28. Chaiteerakij R, Zhang X, Addissie BD, Mohamed EA, Harmsen WS, Theobald PJ, Peters BE, et al. Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl 2015; 21: 599-606.

  29. Toso C, Dupuis-Lozeron E, Majno P, Berney T, Kneteman NM, Perneger T, Morel P, et al. A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list. Hepatology 2012; 56: 149-56.

  30. Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY. Alpha- fetoprotein level?>?1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl 2014; 20: 945-51.

  31. Xu X, Lu D, Ling Q, Wei X, Wu J, Zhou L, Yan S, et al. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria. Gut 2015; 65: 1035-41.

  32. Samoylova ML, Dodge JL, Yao FY, Roberts JP. Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl 2014; 20: 937-44.

  33. Palmer WC, Lee D, Burns J, Croome K, Rosser B, Patel T, Keaveny AP. Liver transplantation for hepatocellular carcinoma: impact of wait time at a single center. Ann Hepatol 2017; 16(3): 402-11.




2020     |     www.medigraphic.com